336 related articles for article (PubMed ID: 33339110)
1. Nano-Biomimetic Drug Delivery Vehicles: Potential Approaches for COVID-19 Treatment.
Witika BA; Makoni PA; Mweetwa LL; Ntemi PV; Chikukwa MTR; Matafwali SK; Mwila C; Mudenda S; Katandula J; Walker RB
Molecules; 2020 Dec; 25(24):. PubMed ID: 33339110
[TBL] [Abstract][Full Text] [Related]
2. Macrophage biomimetic nanocarriers for anti-inflammation and targeted antiviral treatment in COVID-19.
Tan Q; He L; Meng X; Wang W; Pan H; Yin W; Zhu T; Huang X; Shan H
J Nanobiotechnology; 2021 Jun; 19(1):173. PubMed ID: 34112203
[TBL] [Abstract][Full Text] [Related]
3. Human respiratory viral infections: Current status and future prospects of nanotechnology-based approaches for prophylaxis and treatment.
Dawre S; Maru S
Life Sci; 2021 Aug; 278():119561. PubMed ID: 33915132
[TBL] [Abstract][Full Text] [Related]
4. Nanotheranostics against COVID-19: From multivalent to immune-targeted materials.
Hassanzadeh P
J Control Release; 2020 Dec; 328():112-126. PubMed ID: 32882269
[TBL] [Abstract][Full Text] [Related]
5. Polymer-based nano-therapies to combat COVID-19 related respiratory injury: progress, prospects, and challenges.
Rana MM
J Biomater Sci Polym Ed; 2021 Jun; 32(9):1219-1249. PubMed ID: 33787467
[TBL] [Abstract][Full Text] [Related]
6. The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections.
Ferrara F; Vitiello A
Naunyn Schmiedebergs Arch Pharmacol; 2021 Jul; 394(7):1589-1593. PubMed ID: 34151392
[TBL] [Abstract][Full Text] [Related]
7. Nanomedicine for the SARS-CoV-2: State-of-the-Art and Future Prospects.
Varahachalam SP; Lahooti B; Chamaneh M; Bagchi S; Chhibber T; Morris K; Bolanos JF; Kim NY; Kaushik A
Int J Nanomedicine; 2021; 16():539-560. PubMed ID: 33519200
[TBL] [Abstract][Full Text] [Related]
8. Targeting SARS-CoV-2 Spike Protein/ACE2 Protein-Protein Interactions: a Computational Study.
Pirolli D; Righino B; De Rosa MC
Mol Inform; 2021 Jun; 40(6):e2060080. PubMed ID: 33904240
[TBL] [Abstract][Full Text] [Related]
9. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
Rohilla S
Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
[TBL] [Abstract][Full Text] [Related]
10. The roles of Eph receptors, neuropilin-1, P2X7, and CD147 in COVID-19-associated neurodegenerative diseases: inflammasome and JaK inhibitors as potential promising therapies.
Zalpoor H; Akbari A; Samei A; Forghaniesfidvajani R; Kamali M; Afzalnia A; Manshouri S; Heidari F; Pornour M; Khoshmirsafa M; Aazami H; Seif F
Cell Mol Biol Lett; 2022 Feb; 27(1):10. PubMed ID: 35109786
[TBL] [Abstract][Full Text] [Related]
11. Development of nanoparticle-delivery systems for antiviral agents: A review.
Delshadi R; Bahrami A; McClements DJ; Moore MD; Williams L
J Control Release; 2021 Mar; 331():30-44. PubMed ID: 33450319
[TBL] [Abstract][Full Text] [Related]
12. Biomimetics in drug delivery systems: A critical review.
Sheikhpour M; Barani L; Kasaeian A
J Control Release; 2017 May; 253():97-109. PubMed ID: 28322976
[TBL] [Abstract][Full Text] [Related]
13. Dual targeting of Toll-like receptor 4 and angiotensin-converting enzyme 2: a proposed approach to SARS-CoV-2 treatment.
Kate Gadanec L; Qaradakhi T; Renee McSweeney K; Ashiana Ali B; Zulli A; Apostolopoulos V
Future Microbiol; 2021 Mar; 16():205-209. PubMed ID: 33569984
[No Abstract] [Full Text] [Related]
14. A potential solution to avoid overdose of mixed drugs in the event of Covid-19: Nanomedicine at the heart of the Covid-19 pandemic.
Duverger E; Herlem G; Picaud F
J Mol Graph Model; 2021 May; 104():107834. PubMed ID: 33516966
[TBL] [Abstract][Full Text] [Related]
15. A systems-level study reveals host-targeted repurposable drugs against SARS-CoV-2 infection.
Chen F; Shi Q; Pei F; Vogt A; Porritt RA; Garcia G; Gomez AC; Cheng MH; Schurdak ME; Liu B; Chan SY; Arumugaswami V; Stern AM; Taylor DL; Arditi M; Bahar I
Mol Syst Biol; 2021 Aug; 17(8):e10239. PubMed ID: 34339582
[TBL] [Abstract][Full Text] [Related]
16. Review of studies of severe acute respiratory syndrome related coronavirus-2 pathogenesis in human organoid models.
Egilmezer E; Rawlinson WD
Rev Med Virol; 2021 Nov; 31(6):e2227. PubMed ID: 33763936
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
Shukla AK; Banerjee M
High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
[TBL] [Abstract][Full Text] [Related]
18. Current understanding on molecular drug targets and emerging treatment strategy for novel coronavirus-19.
Raj K; Kaur K; Gupta GD; Singh S
Naunyn Schmiedebergs Arch Pharmacol; 2021 Jul; 394(7):1383-1402. PubMed ID: 33961065
[TBL] [Abstract][Full Text] [Related]
19. Implication of nanotechnology-based approaches to combat SARS-CoV-2 infection.
Heidari M; Salmanpour M; Tamaddon AM
Indian J Pharmacol; 2021; 53(1):78-79. PubMed ID: 33976004
[No Abstract] [Full Text] [Related]
20. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
